

# Appendix 4C

## Quarterly report for entities admitted on the basis of commitments

Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10

Name of entity

MMJ PHYTOTECH LIMITED

ABN

91 601 236 417

Quarter ended ("current quarter")

30 September 2015

### Consolidated statement of cash flows

Cash flows related to operating activities		Current Quarter \$A'ooo	Year to Date (3 months) \$A'ooo
1.1	Receipts from customers	17	17
1.2	Payments for (a) staff costs	(558)	(558)
	(b) advertising and marketing	(105)	(105)
	(c) research and development	(116)	(116)
	(d) leased assets	-	-
	(e) other working capital	(1,818)	(1,818)
1.3	Dividends received	-	-
1.4	Interest and other items of a similar nature received	10	10
1.5	Interest and other costs of finance paid	(23)	(23)
1.6	Income taxes paid	-	-
1.7	Other (provide details if material)	-	-
<b>Net operating cash flows</b>		<b>(2,593)</b>	<b>(2,593)</b>

+ See chapter 19 for defined terms.

**Appendix 4C**  
**Quarterly report for entities**  
**admitted on the basis of commitments**

	Current Quarter \$A'000	Year to Date (3 months) \$A'000
1.8 Net operating cash flows (carried forward)	(2,593)	(2,593)
<b>1.9 Cash flows related to investing activities</b>		
Payment for acquisition of:		
(a) businesses (item 5)	-	-
(b) equity investments	-	-
(c) intellectual property	(1)	(1)
(d) physical non-current assets	(1,222)	(1,222)
(e) other non-current assets	-	-
<b>1.10 Proceeds from disposal of:</b>		
(a) businesses (item 5)	-	-
(b) equity investments	-	-
(c) intellectual property	-	-
(d) physical non-current assets	-	-
(e) other non-current assets	-	-
<b>1.11 Loans to other entities</b>	-	-
<b>1.12 Loans repaid by other entities</b>	289	289
<b>1.13 Other (provide details if material)</b>	-	-
<b>Net investing cash flows</b>	(934)	(934)
<b>1.14 Total operating and investing cash flows</b>	(3,527)	(3,527)
<b>Cash flows related to financing activities</b>		
<b>1.15 Proceeds from issues of shares, options, etc.</b>	4,800	4,800
<b>1.16 Proceeds from sale of forfeited shares</b>	-	-
<b>1.17 Proceeds from borrowings</b>	-	-
<b>1.18 Repayment of borrowings</b>	-	-
<b>1.19 Dividends paid</b>	-	-
<b>1.20 Other (capital raising costs)</b>	(247)	(247)
<b>Net financing cash flows</b>	4,553	4,553
<b>Net increase (decrease) in cash held</b>	1,026	1,026
<b>1.21 Cash at beginning of quarter/year to date</b>	1,910	1,910
<b>1.22 Exchange rate adjustments to item 1.20</b>	-	-
<b>1.23 Cash at end of quarter</b>	2,936	2,936

+ See chapter 19 for defined terms.

## Payments to directors of the entity and associates of the directors

## Payments to related entities of the entity and associates of the related entities

		Current quarter \$A'000
1.24	Aggregate amount of payments to the parties included in item 1.2	173
1.25	Aggregate amount of loans to the parties included in item 1.11	-
1.26	Explanation necessary for an understanding of the transactions	
	Directors fees and consulting fees.	

## Non-cash financing and investing activities

- 2.1 Details of financing and investing transactions which have had a material effect on consolidated assets and liabilities but did not involve cash flows

On 27 July 2015 the Company completed a merger transaction with MMJ Bioscience Inc, under which it issued 51,000,000 Shares to the vendors of MMJ Bioscience Inc as consideration

- 2.2 Details of outlays made by other entities to establish or increase their share in businesses in which the reporting entity has an interest

None

## Financing facilities available

Add notes as necessary for an understanding of the position.

	Amount available \$A'000	Amount used \$A'000
3.1 Loan facilities	-	-
3.2 Credit standby arrangements	-	-

+ See chapter 19 for defined terms.

**Appendix 4C**  
**Quarterly report for entities**  
**admitted on the basis of commitments**

---

**Reconciliation of cash**

Reconciliation of cash at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts is as follows.		Current quarter \$A'ooo	Previous quarter \$A'ooo
4.1	Cash on hand and at bank	2,630	1,880
4.2	Deposits at call		
4.3	Bank overdraft		
4.4	Other (term deposits)	306	30
<b>Total: cash at end of quarter</b> (item 1.23)		<b>2,936</b>	<b>1,910</b>

**Acquisitions and disposals of business entities**

	Acquisitions (Item 1.9(a))	Disposals (Item 1.10(a))
5.1	Name of entity	MMJ Bioscience Inc and its subsidiaries
5.2	Place of incorporation or registration	Canada and Switzerland
5.3	Consideration for acquisition or disposal	51,000,000 Shares with a further 17,000,000 to be issued subject to the satisfaction of certain milestones.
5.4	Total net assets	\$1,802,472
5.5	Nature of business	Medical cannabis cultivation and pharmaceutical and nutraceutical products developer and distributor.

---

+ See chapter 19 for defined terms.

## Compliance statement

- 1 This statement has been prepared under accounting policies which comply with accounting standards as defined in the Corporations Act (except to the extent that information is not required because of note 2) or other standards acceptable to ASX.
- 2 This statement does ~~/does not~~\* give a true and fair view of the matters disclosed.

Sign here: .....  ..... Date: 30 October 2015  
(Director/Company secretary)

Print name: Erlyn Dale

## Notes

1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity wanting to disclose additional information is encouraged to do so, in a note or notes attached to this report.
2. The definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report except for any additional disclosure requirements requested by AASB 107 that are not already itemised in this report.
3. **Accounting Standards.** ASX will accept, for example, the use of International Financial Reporting Standards for foreign entities. If the standards used do not address a topic, the Australian standard on that topic (if any) must be complied with.

---

+ See chapter 19 for defined terms.